SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

Longeveron Inc.
Date: July 25, 2025 · CIK: 0001721484 · Accession: 0000000000-25-007853

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

Date
July 25, 2025
Author
Division of
Form
UPLOAD
Company
Longeveron Inc.

Letter

Re: Longeveron Inc. Draft Registration Statement on Form S-1 Submitted July 21, 2025 CIK No. 0001721484 Dear Wa el Hashad:

July 25, 2025

Wa el Hashad Chief Executive Officer Longeveron Inc. 1951 NW 7th Avenue, Suite 520 Miami, FL 33136

This is to advise you that we do not intend to review your registration statement.

We request that you publicly file your registration statement at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Joshua Gorsky at 202-551-7836 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Jennifer Minter, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 July 25, 2025

Wa el Hashad
Chief Executive Officer
Longeveron Inc.
1951 NW 7th Avenue, Suite 520
Miami, FL 33136

 Re: Longeveron Inc.
 Draft Registration Statement on Form S-1
 Submitted July 21, 2025
 CIK No. 0001721484
Dear Wa el Hashad:

 This is to advise you that we do not intend to review your registration
statement.

 We request that you publicly file your registration statement at least
two business
days prior to the requested effective date and time. Please refer to Rules 460
and 461
regarding requests for acceleration. We remind you that the company and its
management are
responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review,
comments, action or absence of action by the staff.

 Please contact Joshua Gorsky at 202-551-7836 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Jennifer Minter, Esq.
</TEXT>
</DOCUMENT>